Actively Recruiting
Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients
Led by Children's Hospital Medical Center, Cincinnati · Updated on 2026-01-22
20
Participants Needed
1
Research Sites
186 weeks
Total Duration
On this page
Sponsors
C
Children's Hospital Medical Center, Cincinnati
Lead Sponsor
S
Sobi, Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
The investigators hypothesize that graft rejection after hematopoietic stem cell transplant (HSCT) is primarily driven by interferon gamma, and prophylactic interferon gamma inhibition in high-risk patients will prevent graft rejection. Additionally, knowledge of emapalumab PK/PD and in vitro mechanistic effects of emapalumab in this novel setting will guide optimization of dosing regimens and treatment approaches in future studies.
CONDITIONS
Official Title
Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients undergoing allogeneic HSCT at the study institution
- Patients at high risk for graft rejection with at least two risk factors: mismatched or haploidentical donor, ex vivo t-cell depleted graft, or prior graft rejection history
You will not qualify if you...
- Known hypersensitivity to any part of the study medication
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229
Actively Recruiting
Research Team
J
Jessica Anderson, BSN, RN, CCRC
CONTACT
M
Manisha Pathak, MS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here